Skip to main content
SpringerLink
Log in

Ozone: A New Therapeutic Agent in Vascular Diseases

  • Current Opinion
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

In this article, we scientifically evaluate the bio-oxidative procedure known as oxygen-ozone therapy. Research over a decade has established a comprehensive framework for understanding and recommending this type of autohemotherapy in vascular diseases. In contrast, a non-specific immunomodulation therapy, using heavily oxidized and denatured blood, has been recently used in studies involving a total of approximately 3000 patients and has led to ‘disappointing’ results. Such a treatment appears to be an inappropriate example of the so-called minor autohemotherapy, and its poor outcomes may discourage any further studies. Therefore it appears necessary to clarify that the use of only a minimal ozone dose and a valid experimental protocol is likely to produce beneficial results. Millions of people suffer from chronic limb, brain, and heart ischemia, and such patients may benefit if appropriate ozone therapy could be implemented. Accordingly, we propose the need for a well designed, multicenter, clinical trial to be conducted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

Similar content being viewed by others

References

  1. Nakao A, Sugimoto R, Billiar TR, et al. Therapeutic antioxidant medical gas. J Clin Biochem Nutr 2009; 44: 1–13.

    Article  PubMed  CAS  Google Scholar 

  2. Rokitanski O, Rokitanski A, Steiner J, et al. Die ozontherapie bei peripheren, arteriellen Durchblutungs-strörugen; linik, biochemische und blutgasanalytische untersuchungen. Wasser IOA, Ozon-Weltkongress; Berlin, 1981: 53–75.

    Google Scholar 

  3. Matassi R, D’Angelo F, Bisetti P, et al. Terapia con ozono per via parenterale nelle arteropatie obliteranti periferiche: meccanismo biochimico e risultati clinici. Il Giornale di Chirurgia 1987; VIII: 109–11.

    Google Scholar 

  4. De Monte A, van der Zee H, Bocci V. Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. J Altern Complement Med 2005; 11: 363–7.

    Article  PubMed  Google Scholar 

  5. Hernandez F, Menéndez S, Wong R. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic Biol Med 1995; 19: 115–9.

    Article  PubMed  CAS  Google Scholar 

  6. Biedunkiewicz B, Tylicki L, Nieweglowski T, et al. Clinical efficacy of ozonated autohemotherapy in hemodialyzed patients with intermittent claudication: an oxygen controlled study. Int J Artif Organs 2004; 27: 29–34.

    PubMed  CAS  Google Scholar 

  7. Di Paolo N, Bocci V, Garosi G, et al. Extracorporeal blood oxygenation and ozonation (EBOO) in man: preliminary report. Int J Artif Organs 2000; 23: 131–41.

    PubMed  Google Scholar 

  8. Di Paolo N, Bocci V, Salvo DP, et al. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. Int J Artif Organs 2005; 28: 1039–50.

    PubMed  Google Scholar 

  9. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebocontrolled randomised trial. Lancet 2008; 371: 228–36.

    Article  PubMed  CAS  Google Scholar 

  10. Travagli V, Zanardi I, Bernini P, et al. Effects of ozone blood treatment on the metabolite profile of human blood. Int J Toxicol 2010; 29: 165–74.

    Article  PubMed  CAS  Google Scholar 

  11. Mustafa MG. Biochemical basis of ozone toxicity. Free Radic Biol Med 1990; 9: 245–65.

    Article  PubMed  CAS  Google Scholar 

  12. Pryor WA. Mechanisms of radical formation from reactions of ozone with target molecules in the lung. Free Radic Biol Med 1994; 17: 451–65.

    Article  PubMed  CAS  Google Scholar 

  13. Tager IB, Balmes J, Lurmann F, et al. Chronic exposure to ambient ozone and lung function in young adults. Epidemiology 2005; 16: 751–9.

    Article  PubMed  Google Scholar 

  14. Ruidavets JB, Cournot M, Cassadou S, et al. Ozone air pollution is associated with acute myocardial infarction. Circulation 2005; 111: 563–9.

    Article  PubMed  CAS  Google Scholar 

  15. Kampa M, Castanas E. Human health effects of air pollution. Environ Pollut 2008; 151: 362–7.

    Article  PubMed  CAS  Google Scholar 

  16. Jerrett M, Burnett RT, Pope 3rd CA, et al. Long-term ozone exposure and mortality. N Engl J Med 2009; 360: 1085–95.

    Article  PubMed  CAS  Google Scholar 

  17. Bastacky J, Lee CYC, Goerke J, et al. Alveolar lining layer is thin and continuous: low-temperature scanning electron microscopy of rat lung. J Appl Physiol 1995; 79: 1615–28.

    PubMed  CAS  Google Scholar 

  18. Cho HY, Zhang LY, Kleeberger SR. Ozone-induced lung inflammation and hyperreactivity are mediated via tumor necrosis factor-alpha receptors. Am J Physiol Lung Cell Mol Physiol 2001; 280: L537–46.

    PubMed  CAS  Google Scholar 

  19. Last JA, Gohil K, Mathrani VC, et al. Systemic responses to inhaled ozone in mice: cachexia and down-regulation of liver xenobiotic metabolizing genes. Toxicol Appl Pharmacol 2005; 208: 117–26.

    Article  PubMed  CAS  Google Scholar 

  20. Uppu RM, Cueto R, Squadrito GL, et al. What does ozone react with at the air/lung interface? Model studies using human red blood cell membranes. Arch Biochem Biophys 1995; 319: 257–66.

    Article  PubMed  CAS  Google Scholar 

  21. Bocci V. Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharmacol 2006; 216: 493–504.

    Article  PubMed  CAS  Google Scholar 

  22. Search strategy used to create CAM on PubMed (PubMed’s Complementary Medicine Subset) [online]. Available from URL: http: //www.nlm.nih.gov/ bsd/pubmed_subsets/comp_med_strategy.html [Accessed 2010 Mar 2].

  23. Forman HJ. Hydrogen peroxide: the good, the bad and the ugly. In: Valacchi G, Davis P, editors. Oxidants in biology. Dordrecht: Springer, 2008: 1–17.

    Chapter  Google Scholar 

  24. Barrera G, Pizzimenti S, Dianzani MU. Lipid peroxidation: control of cell proliferation, cell differentiation and cell death. Mol Aspects Med 2008; 29: 1–8.

    Article  PubMed  CAS  Google Scholar 

  25. Yang G, Wu L, Jiang B, et al. H2 S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008; 322: 587–90.

    Article  PubMed  CAS  Google Scholar 

  26. Long EK, Picklo Sr MJ. Trans-4-hydroxy-2-hexenal, a product of n-3 fatty acid peroxidation: make some room HNE. Free Radic Biol Med 2010; doi: 10.1016/j. Epub.

  27. Bocci V, Borrelli E, Travagli V, et al. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev 2009; 29: 646–82.

    Article  PubMed  CAS  Google Scholar 

  28. Battino R, Rettici TR, Tominaga T. The solubility of oxygen and ozone in liquids. J Phys Chem Ref Data 1983; 12: 163–78.

    Article  CAS  Google Scholar 

  29. Pryor WA, Squadrito GL, Friedman M. The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Free Radical Biol Med 1995; 19: 935–41.

    Article  CAS  Google Scholar 

  30. Bocci V. Ozone: a new medical drug. 2nd ed. Dordrecht: Springer Science, 2011.

    Google Scholar 

  31. Bocci V. Scientific and medical aspects of ozone therapy: state of the art. Arch Med Res 2006; 37: 425–35.

    Article  PubMed  CAS  Google Scholar 

  32. Bocci V, Aldinucci C. Biochemical modifications induced in human blood by oxygenation-ozonation. J Biochem Mol Toxicol 2006; 20: 133–8.

    Article  PubMed  CAS  Google Scholar 

  33. Travagli V, Zanardi I, Silvietti A, et al. A physicochemical investigation on the effects of ozone on blood. Int J Biol Macromol 2007; 41: 504–11.

    Article  PubMed  CAS  Google Scholar 

  34. Bocci V, Zanardi I, Michaeli D, et al. Mechanisms of action and chemicalbiological interactions between ozone and body compartments: a critical appraisal of the different administration routes. Curr Drug Ther 2009; 4: 159–73.

    Article  CAS  Google Scholar 

  35. Bocci V, Valacchi G, Corradeschi F, et al. Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J Biol Regul Homeost Agents 1998; 12: 67–75.

    CAS  Google Scholar 

  36. Bocci V, Valacchi G, Corradeschi F, et al. Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. Mediators Inflamm 1998; 7: 313–7.

    CAS  Google Scholar 

  37. Shinriki N, Suzuki T, Takama K, et al. Susceptibilities of plasma antioxidants and erythrocyte constituents to low levels of ozone. Haematologia 1998; 29: 229–39.

    PubMed  CAS  Google Scholar 

  38. Carballal S, Alvarez B, Turell L, et al. Sulfenic acid in human serum albumin. Amino Acids 2007; 32: 543–51.

    Article  PubMed  CAS  Google Scholar 

  39. Aldini G, Vistoli G, Regazzoni L, et al. Albumin is the main nucleophilic target of human plasma: a protective role against proatherogenic electrophilic reactive carbonyl species? Chem Res Toxicol 2008; 21: 824–35.

    Article  PubMed  CAS  Google Scholar 

  40. Mendiratta S, Qu ZC, May JM. Enzyme-dependent ascorbate recycling in human erythrocytes: role of thioredoxin reductase. Free Radic Biol Med 1998; 25: 221–8.

    Article  PubMed  CAS  Google Scholar 

  41. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 1999; 31: 261–72.

    Article  PubMed  CAS  Google Scholar 

  42. Packer L, Roy S, Sen CK. Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 1997; 38: 79–101.

    Article  PubMed  CAS  Google Scholar 

  43. Antunes F, Cadenas E. Estimation of H2 O2 gradients across biomembranes. FEBS Lett 2000; 475: 121–6.

    Article  PubMed  CAS  Google Scholar 

  44. Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006; 8: 243–70.

    Article  PubMed  CAS  Google Scholar 

  45. Miller NJ, Rice-Evans C, Davies MJ, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407–12.

    PubMed  CAS  Google Scholar 

  46. Valacchi G, Bocci V. Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. Mediat Inflamm 2000; 9: 271–6.

    Article  CAS  Google Scholar 

  47. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141–79.

    Article  PubMed  CAS  Google Scholar 

  48. Valacchi G, Bocci V. Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. Mediat Inflamm 1999; 8: 205–9.

    Article  CAS  Google Scholar 

  49. Awasthi YC, Ansari GA, Awasthi S. Regulation of 4-hydroxynonenalmediated signaling by glutathione S-transferase. Methods Enzymol 2005; 401: 379–407.

    Article  PubMed  CAS  Google Scholar 

  50. Yamamoto Y. Fate of lipid hydroperoxides in blood plasma. Free Radic Res 2000; 33: 795–800.

    Article  PubMed  CAS  Google Scholar 

  51. Petras T, Siems WG, Grune T. 4-Hydroxynonenal is degraded to mercapturic acid conjugate in rat kidney. Free Radic Biol Med 1995; 19: 685–8.

    Article  PubMed  CAS  Google Scholar 

  52. Poli G, Schaur RJ, Siems WG, et al. 4-Hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med Res Rev 2008; 28: 569–631.

    Article  PubMed  CAS  Google Scholar 

  53. Takahashi Y, Takahashi S, Yoshimi T, et al. Increases in the mRNA levels of γ-glutamyltransferase and heme oxygenase-1 in the rat lung after ozone exposure. Biochem Pharmacol 1997; 53: 1061–4.

    Article  PubMed  CAS  Google Scholar 

  54. Dianzani MU. 4-Hydroxynonenal and cell signalling. Free Radic Res 1998; 28: 553–60.

    Article  PubMed  CAS  Google Scholar 

  55. Cheng JZ, Sharma R, Yang Y, et al. Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative stress. J Biol Chem 2001; 276: 41213–23.

    Article  PubMed  CAS  Google Scholar 

  56. Yang YS, Sharma R, Sharma A, et al. Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim Pol 2003; 50: 319–36.

    PubMed  CAS  Google Scholar 

  57. Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 2004; 37: 937–45.

    Article  PubMed  CAS  Google Scholar 

  58. Siems W, Grune T. Intracellular metabolism of 4-hydroxynonenal. Mol Aspects Med 2003; 24: 167–75.

    Article  PubMed  CAS  Google Scholar 

  59. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–42.

    PubMed  CAS  Google Scholar 

  60. Hobbs AJ. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci 1997; 18: 484–91.

    PubMed  CAS  Google Scholar 

  61. Wang R. Two’s company, three’s a crowd: can H2 S be the third endogenous gaseous transmitter? FASEB J 2002; 16: 1792–8.

    Article  PubMed  CAS  Google Scholar 

  62. Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radical. Nat Med 2007; 13: 688–94.

    Article  PubMed  CAS  Google Scholar 

  63. Wood KC, Gladwin MT. The hydrogen highway to reperfusion therapy. Nat Med 2007; 13: 673–4.

    Article  PubMed  CAS  Google Scholar 

  64. Calabrese EJ. Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol 2010; 29: 249–61.

    Article  PubMed  Google Scholar 

  65. Benson H, Friedman R. Harnessing the power of the placebo effect and renaming it “remembered wellness”. Annu Rev Med 1996; 47: 193–9.

    Article  PubMed  CAS  Google Scholar 

  66. Schulz S, Häussier U, Mandic R, et al. Treatment with ozone/oxygen-pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas. Int J Cancer 2008; 122: 2360–7.

    Article  PubMed  CAS  Google Scholar 

  67. Viru A, Tendzegolskis Z. Plasma endorphin species during dynamic exercise in humans. Clin Physiol 1995; 15: 73–9.

    Article  PubMed  CAS  Google Scholar 

  68. Goldstein BD, Balchum OJ. Effect of ozone on lipid peroxidation in the red blood cell. Exp Biol Med 1967; 126: 356–8.

    CAS  Google Scholar 

  69. Bocci V, Borrelli E, Valacchi G, et al. Quasi-total-body exposure to an oxygenozone mixture in a sauna cabin. Eur J Appl Physiol Occup Physiol 1999; 80: 549–54.

    Article  PubMed  CAS  Google Scholar 

  70. Bocci V, Zanardi I, Travagli V, et al. Oxygenation-ozonation of blood during extracorporeal circulation: in vitro efficiency of a new gas exchange device. Artif Organs 2007; 31: 743–8.

    Article  PubMed  CAS  Google Scholar 

  71. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008; 60: 79–127.

    Article  PubMed  CAS  Google Scholar 

  72. Jacobs MT. Untersuchung uber zwishenfalle und typische komplikationen in der ozon-sauerstofftherapie. OzoNachrichten 1982; 5: 1–5.

    Google Scholar 

  73. Allegra C, Antignani PL, Schachter I, et al. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease. Ann Vasc Surg 2008; 22: 552–8.

    Article  PubMed  Google Scholar 

  74. Tylicki L, NiewgŁowski T, Biedunkiewicz B, et al. Beneficial clinical effects of ozonated autohemotherapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs: pilot study. Int J Artif Organs 2001; 24: 79–82.

    PubMed  CAS  Google Scholar 

  75. Tylicki L, Nieweglowski T, Biedunkiewicz B, et al. The influence of ozonated autohemotherapy on oxidative stress in hemodialyzed patients with atherosclerotic ischemia of lower limbs. Int J Artif Organs 2003; 26: 297–303.

    PubMed  CAS  Google Scholar 

  76. Tylicki L, Biedunkiewicz B, Nieweglowski T, et al. Ozonated autohemotherapy in patients on maintenance hemodialysis: influence on lipid profile and endothelium. Artif Organs 2004; 28: 234–7.

    Article  PubMed  Google Scholar 

  77. Bulmer J, Bolton AE, Pockley AG. Effect of combined heat, ozonation and ultraviolet irradiation (VasoCare) on heat shock protein expression by peripheral blood leukocyte populations. J Biol Regul Homeost Agents 1997; 11: 104–10.

    PubMed  CAS  Google Scholar 

  78. Bocci V, Travagli V, Zanardi I. Maybe oxygen-ozone therapy blocks the progression of cardiovascular disorders? Cardiovasc Hematol Disord Drug Targets 2009; 9: 78–85.

    Article  PubMed  CAS  Google Scholar 

  79. Garber GE, Cameron DW, Hawley-Foss N, et al. The use of ozone-treated blood in the therapy of HIV infection and immune disease: a pilot study of safety and efficacy. AIDS 1991; 5: 981–4.

    Article  PubMed  CAS  Google Scholar 

  80. Hooker MH, Gazzard BG. Ozone-treated blood in the treatment of HIV infection [letter]. AIDS 1992; 6: 131.

    Article  PubMed  CAS  Google Scholar 

  81. Olin JW. A multicenter, randomized, double-blind, placebo-controlled study of immune modulation therapy in patients with symptomatic peripheral arterial diseases: the SIMPADICO trial. Smaller Late-Breaking Clinical Trials I, American College of Cardiology 55th Annual Scientific Sessions; 2006 Mar 11–14; Atlanta (GA).

  82. Torre-Amione G, Sestier F, Radovancevic B, et al. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004; 44: 1181–6.

    Article  PubMed  Google Scholar 

  83. Sliwa K, Ansari AA. Immunosuppression as therapy for congestive heart failure. Lancet 2008; 371: 184–6.

    Article  PubMed  Google Scholar 

  84. Bocci V. Non-specific immunomodulation in chronic heart failure [letter]. Lancet 2008; 371: 2083.

    Article  PubMed  Google Scholar 

  85. Bocci V. The failure of the ACCLAIM trial is due to an irrational technology. Int J Cardiol 2010; 139: 304–5.

    Article  PubMed  Google Scholar 

  86. Bocci V, Zanardi I, Travagli V. The irrationality of a non-specific immunomodulation therapy used in cardiovascular diseases deserves a critical comment. Atherosclerosis 2010; 211: 38–9.

    Article  PubMed  CAS  Google Scholar 

  87. Bocci V, Aldinucci C, Mosci F, et al. Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm 2007; 26785. doi: 10.1155/2007/26785.

  88. Di Filippo C, Luongo M, Marfella R, et al. Oxygen/ozone protects the heart from acute myocardial infarction through local increase of eNOS activity and endothelial progenitor cells recruitment. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 287–91.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No funding was used in the preparation of this article. The authors have no conflicts of interest that are relevant to the content of this article.

Author information

Authors and Affiliations

  1. Department of Physiology, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy

    Velio Bocci MD (Emeritus Professor of Physiology)

  2. Department of Pharmaceutical Chemistry and Technology, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy

    Iacopo Zanardi & Valter Travagli PharmD (Associate Professor of Pharmaceutical Technology and Chief of the Graduate School of Hospital Pharmacy)

Authors
  1. Velio Bocci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iacopo Zanardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valter Travagli PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Velio Bocci MD or Valter Travagli PharmD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bocci, V., Zanardi, I. & Travagli, V. Ozone: A New Therapeutic Agent in Vascular Diseases. Am J Cardiovasc Drugs 11, 73–82 (2011). https://doi.org/10.2165/11539890-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11539890-000000000-00000

Keywords

Search

Navigation